Please ensure Javascript is enabled for purposes of website accessibility

Daily Posts Archive

[form src='/form/best-stocks’]

When the stock market finally gets going on the upside, paying special attention to volume spikes allow us to clue in on the advance’s best stocks.
Today’s dividend investment is a brand new stock, created in August, that is already yielding over 9%. From Carla Pasternak’s High-Yield Investing:SandRidge Permian Trust (PER) began trading on August 11, 2011. Its sponsor, SandRidge Energy (SD) created the trust by spinning off 509 producing wells and 888 development wells in...
Golf is a lot like investing in growth stocks; you’ve got to learn, practice and repeat until you’ve got it down.
Complacency is never a good sign in the stock market. The market climbs a wall of worry, for which fear is needed. So it’s reasonable that, after eight weeks of persistent upward movement, many investors and advisors are saying, “too good to be true.” And yet... the market keeps rising. Recently,...
One of the best ways to put money into great growth stocks is by keeping a list of leading stocks.
Emerging markets offer a high potential for growth in your portfolio.
“Founded in 1904, Beam, Inc. (BEAM) is a major producer of distilled spirits, including bourbon, whiskey, tequila, scotch, rum, vodka, cognac and gin, whose brands include Jim Beam, Maker’s Mark, Sauza, Canadian Club, Courvoisier, Teacher’s, Cruzan, Hornitos and DeKuyper. It recently acquired Dublin-based Cooley Distillery, entering the fast-growing...
“For EMC Corp. (EMC), a cloudy forecast suggests a sunny outcome. The company primarily sells storage devices and software that help companies handle the avalanche of electronic data. But EMC is also positioned to benefit from the migration to cloud computing, which allows companies to reduce costs by...
In today’s Stock Market Crash Course, I quote several experts who share the dominant view that a 5%-10% correction is imminent, but also find two who say corrections never happen when you most expect them.
The expected Alzheimer’s drugs, if approved, will face a more challenging environment on every front.